Creative Medical Technology Holdings Inc
CELZ
查看详细走势图
2.220USD
+0.050+2.30%
收盘 12/24, 13:00（美东）报价延迟15分钟
5.73M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.30%
5天
+4.96%
1月
-18.38%
6月
-14.62%
今年开始到现在
-3.90%
1年
+5.21%
查看详细走势图
TradingKey Creative Medical Technology Holdings Inc股票评分
单位: USD 更新时间: 2025-12-24操作建议
Creative Medical Technology Holdings Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名129/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价20.00。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Creative Medical Technology Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
1
位分析师
买入
评级
20.000
目标均价
+800.90%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Creative Medical Technology Holdings Inc亮点
亮点风险
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
Creative Medical Technology Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Creative Medical Technology Holdings Inc简介
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
公司代码CELZ
公司Creative Medical Technology Holdings Inc
CEOWarbington (Timothy)
网址https://creativemedicaltechnology.com/
常见问题
Creative Medical Technology Holdings Inc(CELZ)的当前股价是多少？
Creative Medical Technology Holdings Inc(CELZ)的当前股价是 2.220。
Creative Medical Technology Holdings Inc的股票代码是什么？
Creative Medical Technology Holdings Inc的股票代码是CELZ。
Creative Medical Technology Holdings Inc股票的52周最高点是多少？
Creative Medical Technology Holdings Inc股票的52周最高点是6.900。
Creative Medical Technology Holdings Inc股票的52周最低点是多少？
Creative Medical Technology Holdings Inc股票的52周最低点是1.690。
Creative Medical Technology Holdings Inc的市值是多少？
Creative Medical Technology Holdings Inc的市值是5.73M。
Creative Medical Technology Holdings Inc的净利润是多少？
Creative Medical Technology Holdings Inc的净利润为-5.49M。
现在Creative Medical Technology Holdings Inc(CELZ)的股票是买入、持有还是卖出？
根据分析师评级，Creative Medical Technology Holdings Inc(CELZ)的总体评级为买入，目标价格为20.000。
Creative Medical Technology Holdings Inc(CELZ)股票的每股收益（EPS TTM）是多少
Creative Medical Technology Holdings Inc(CELZ)股票的每股收益（EPS TTM）是-2.922。
相关品种
